Erasca (NASDAQ:ERAS) Now Covered by Analysts at Leerink Partners

Erasca logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Leerink Partners initiated coverage of Erasca with an Outperform rating and a $35 price target, implying 142.9% upside from the previous close.
  • Analyst sentiment is broadly positive: Erasca has a “Moderate Buy” consensus rating and an average price target of $23.17, based on nine Buy, two Hold, and one Sell rating.
  • Shares fell 4.6% to $14.41, and the company reported a quarterly loss of $0.15 per share, missing analysts’ $0.13 loss estimate.
  • MarketBeat previews top five stocks to own in December.

Analysts at Leerink Partners began coverage on shares of Erasca (NASDAQ:ERAS - Get Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage set an "outperform" rating and a $35.00 price target on the stock. Leerink Partners's target price indicates a potential upside of 142.90% from the company's previous close.

Several other equities analysts also recently weighed in on ERAS. Guggenheim lifted their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Morgan Stanley upped their price target on shares of Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a research note on Monday, July 20th. Bank of America raised their price objective on shares of Erasca from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Friday, August 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a research note on Tuesday, September 8th. Finally, HC Wainwright boosted their target price on shares of Erasca from $18.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Erasca presently has an average rating of "Moderate Buy" and a consensus price target of $23.17.

Read Our Latest Stock Report on Erasca

Erasca Stock Down 4.6%

ERAS traded down $0.70 during trading hours on Tuesday, hitting $14.41. The stock had a trading volume of 1,266,914 shares, compared to its average volume of 5,804,983. Erasca has a 1 year low of $2.71 and a 1 year high of $24.28. The company's fifty day simple moving average is $14.94 and its 200 day simple moving average is $15.28. The stock has a market cap of $5.04 billion, a PE ratio of -14.59 and a beta of 0.68.

Erasca (NASDAQ:ERAS - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). As a group, equities analysts expect that Erasca will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Nykredit A S bought a new position in shares of Erasca in the second quarter valued at approximately $29,000. Allworth Financial LP bought a new stake in Erasca during the 2nd quarter worth approximately $34,000. EverSource Wealth Advisors LLC lifted its stake in Erasca by 77.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company's stock worth $69,000 after purchasing an additional 1,859 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Erasca in the 2nd quarter worth approximately $80,000. Finally, KBC Group NV purchased a new stake in Erasca in the 1st quarter worth approximately $81,000. Hedge funds and other institutional investors own 67.78% of the company's stock.

Trending Headlines about Erasca

Here are a few of the latest headlines about ERAS:

  • Positive Sentiment: Erasca will present updated Phase 1 data for ERAS-0015 at a virtual investor event on November 20. The company says early dose-escalation results showed favorable safety and tolerability, with partial responses in several patients, including at low doses. These are preliminary clinical findings, and the event may be a near-term catalyst. Erasca investor event and Phase 1 update
  • Positive Sentiment: The company also highlighted promising preclinical results for ERAS-4001, its investigational pan-KRAS inhibitor, adding potential longer-term pipeline upside. The findings are preclinical and do not establish clinical benefit. Erasca investor event announcement
  • Negative Sentiment: HC Wainwright cut its EPS forecasts, including FY2026 to a loss of $0.54 per share from $0.51, and reduced its FY2027–FY2030 estimates substantially. The firm nevertheless maintained its Buy rating and $22 price target, which may partly offset the concern over wider projected losses. Erasca analyst coverage

Erasca Company Profile

(Get Free Report)

Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company's pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.

Further Reading

Analyst Recommendations for Erasca (NASDAQ:ERAS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Erasca Right Now?

Before you consider Erasca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.

While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines